Optimizing the safety of biologic therapy for IBD. (Q37687869)

22 August 2017

1 reference

title

Optimizing the safety of biologic therapy for IBD. (English)

1 reference

22 August 2017

3

Remo Panaccione

1 reference

22 August 2017

Shanika de Silva

1

1 reference

22 August 2017

Shane Devlin

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Nature Reviews Gastroenterology & Hepatology

22 August 2017

published in

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

93-101

1 reference

Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Inflammatory bowel disease: etiology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Infliximab for the treatment of fistulas in patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Infliximab maintenance therapy for fistulizing Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Infliximab for induction and maintenance therapy for ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Certolizumab pegol for the treatment of Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Maintenance therapy with certolizumab pegol for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Guidelines for immunizations in patients with inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Adalimumab safety in global clinical trials of patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Biologic therapy of inflammatory bowel disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Optimizing anti-TNF treatment in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Infliximab and the risk of latent viruses reactivation in active Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Risks and benefits of biologic therapy for inflammatory bowel diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Intestinal cancer risk and mortality in patients with Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Treatment with biologic therapies and the risk of cancer in patients with IBD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Inflammatory bowel disease is not associated with an increased risk of lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Risk of haematopoietic cancer in patients with inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Cancer risk in patients with inflammatory bowel disease: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Hepatosplenic T cell lymphoma in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Risk of Cervical Abnormalities in Women With Inflammatory Bowel Disease: A Population-Based Nested Case-Control Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Lack of association between cervical dysplasia and IBD: a large case-control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Abnormal Pap smears in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.221

4 Integrin blockade in inflammatory bowel disease

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20134491

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Natalizumab: overview of its pharmacology and safety.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20134491

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20134491

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRGASTRO.2009.221

1 reference

22 August 2017

1 reference